Will The Magnificent 7 Stocks Go Up This Year?
2025 was another banner year for the Magnificent Seven stocks,…
Buy
52
SKIN Quote, Financials, Valuation and Earnings
Last price:
$1.46
Seasonality move
:
6.87%
Day range:
$1.45 - $1.59
52-week range:
$0.78 - $2.69
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.67x
P/B ratio:
3.03x
Volume:
416.6K
Avg. volume:
598.5K
1-year change:
-17.51%
Market cap:
$198.9M
Revenue:
$334.3M
EPS (TTM):
-$0.22
Analysts' Opinion
-
Consensus RatingThe Beauty Health Co. has received a consensus rating of Hold. The company's average rating is a Hold based on 1 Buy rating, 6 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $1.93, The Beauty Health Co. has an estimated upside of 23.93% from its current price of $1.46.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $1.50 representing 100% downside risk from its current price of $1.46.
Fair Value
-
According to the consensus of 7 analysts, The Beauty Health Co. has 23.93% upside to fair value with a price target of $1.93 per share.
SKIN vs. S&P 500
-
Over the past 5 trading days, The Beauty Health Co. has overperformed the S&P 500 by 11.21% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
The Beauty Health Co. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
The Beauty Health Co. revenues have been falling on a year-over-year basis for 8 quarters in a row. In the most recent quarter The Beauty Health Co. reported revenues of $70.7M.
Earnings Growth
-
The Beauty Health Co. has grown year-over-year earnings for 3 quarters straight. In the most recent quarter The Beauty Health Co. reported earnings per share of -$0.09.
Enterprise value:
358.5M
EV / Invested capital:
--
Price / LTM sales:
0.67x
EV / EBIT:
--
EV / Revenue:
1.19x
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
10.51x
Price / Operating cash flow:
5.91x
Enterprise value / EBITDA:
114.20x
Gross Profit (TTM):
$195.7M
Return On Assets:
-1.91%
Net Income Margin (TTM):
-3.89%
Return On Equity:
-19.76%
Return On Invested Capital:
-2.13%
Operating Margin:
-8.84%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $399.3M | $347.6M | $301.9M | $78.8M | $70.7M | |
| Gross Profit | $175.9M | $175.7M | $195.7M | $40.6M | $45.6M | |
| Operating Income | -$115M | -$78.9M | -$28.1M | -$21.5M | -$6.2M | |
| EBITDA | -$85.5M | -$41.9M | -$1.6M | -$12M | $2.2M | |
| Diluted EPS | -$0.64 | -$0.42 | -$0.22 | -$0.15 | -$0.09 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $797.8M | $892.4M | $738M | $485M | $308.4M | |
| Total Assets | $997.9M | $1.1B | $973.1M | $699.5M | $503.6M | |
| Current Liabilities | $49.5M | $76.4M | $125.9M | $73.9M | $61.9M | |
| Total Liabilities | $1.1B | $846.9M | $883.1M | $639.8M | $438M | |
| Total Equity | -$142.1M | $257.9M | $90M | $59.7M | $65.7M | |
| Total Debt | $731M | $744.5M | $747.4M | $563.5M | $373.9M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $21.5M | -$5.5M | $38.8M | $10.3M | $9.6M | |
| Cash From Investing | -$32.2M | -$8.1M | -$4.6M | -$2.1M | -$1.1M | |
| Cash From Financing | -$108.6M | -$188.9M | -$175.2M | -$204K | -$803K | |
| Free Cash Flow | $7.8M | -$13.6M | $34.1M | $8.2M | $8.6M | |
SKIN
Sector
Market Cap
$198.9M
$119.3M
Price % of 52-Week High
57.99%
72.12%
Dividend Yield
0%
0%
Shareholder Yield
-45.95%
2.32%
1-Year Price Total Return
-11.86%
-4.41%
Beta (5-Year)
1.162
0.255
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$1.45
200-day SMA
Sell
Level
$1.62
Bollinger Bands (100)
Sell
Level
1.31 - 2.05
Chaikin Money Flow
Sell
Level
-199.9K
20-day SMA
Sell
Level
$1.46
Relative Strength Index (RSI14)
Buy
Level
50.51
ADX Line
Buy
Level
19.15
Williams %R
Sell
Level
-11.1111
50-day SMA
Buy
Level
$1.42
MACD (12, 26)
Buy
Level
0.34
25-day Aroon Oscillator
Sell
Level
-24
On Balance Volume
Neutral
Level
166.7K
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (0.0665)
Sell
CA Score
(Annual)
Level (-2.6162)
Buy
Beneish M-Score
(Annual)
Level (-3.533)
Buy
Momentum Score
Level (5)
Sell
Ohlson Score
Level (3.8907)
Buy
Piotroski F Score
(Annual)
Level (7)
Buy
Quality Ratio Score
Level (8)
Sell
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
The Beauty Health Co. engages in the design, development, manufacture, marketing, and sale of esthetic technologies and products. Its brands include Hydrafacial, SkinStylus, and Keravive. The company was founded in 1997 and is headquartered in Long Beach, CA.
Stock Forecast FAQ
In the current month, SKIN has received 1 Buy ratings 6 Hold ratings, and 0 Sell ratings. The SKIN average analyst price target in the past 3 months is $1.93.
-
Where Will The Beauty Health Co. Stock Be In 1 Year?
According to analysts, the consensus estimate is that The Beauty Health Co. share price will rise to $1.93 per share over the next 12 months.
-
What Do Analysts Say About The Beauty Health Co.?
Analysts are divided on their view about The Beauty Health Co. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that The Beauty Health Co. is a Sell and believe this share price will drop from its current level to $1.50.
-
What Is The Beauty Health Co.'s Price Target?
The price target for The Beauty Health Co. over the next 1-year time period is forecast to be $1.93 according to 7 Wall Street analysts, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 6 analysts rate the stock a Hold.
-
Is SKIN A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for The Beauty Health Co. is a Hold. 6 of 7 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of SKIN?
You can purchase shares of The Beauty Health Co. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase The Beauty Health Co. shares.
-
What Is The The Beauty Health Co. Share Price Today?
The Beauty Health Co. was last trading at $1.46 per share. This represents the most recent stock quote for The Beauty Health Co.. Yesterday, The Beauty Health Co. closed at $1.46 per share.
-
How To Buy The Beauty Health Co. Stock Online?
In order to purchase The Beauty Health Co. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get SKIN Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
SKIN
Sector
P/E ratio
--
16.80x
PEG ratio
0.00x
0.13x
P/B ratio
3.03x
1.49x
Price / LTM sales
0.67x
0.52x
Growth Metrics
SKIN
Sector
Revenue growth
-10.34%
2.83%
Earnings growth
41.05%
1.78%
Revenue (5-year growth)
14.94%
3.32%
Earnings forecast
-$0.05
$0.28
Profitability
SKIN
Sector
Profitability FY 2024
$190.3M
$263.1M
Return on invested capital
-2.13%
4.37%
Return on assets
-1.91%
3.03%
Return on equity
-19.76%
7.59%
Earnings Date
Last Earnings Date
Nov
6
Next Earnings Date
Mar
11
Estimated Next Earnings Date
Feb
5
Balance Sheet
SKIN
Sector
Total cash
$219.4M
$87.3M
Short term investments
--
$31.1M
Total assets
$685.7M
$1.1B
Long term debt
$373.9M
$6.7M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Planet Labs Stock Rally So Much?
Satellite imaging startup Planet Labs (NYSE:PL), after years of disappointing…
Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Buy
51
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
100
ATGL alert for Jan 10
Alpha Technology Group Ltd. [ATGL] is up 47.05% over the past day.
Buy
65
RGC alert for Jan 10
Regencell Bioscience Holdings Ltd. [RGC] is up 10.55% over the past day.
Sell
50
NAIL alert for Jan 10
Direxion Daily Homebuilders & Supplies Bull 3X Shs [NAIL] is up 18.52% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
